May 13, 2024Open Access

Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis

Key Points

Key points are not available for this paper at this time.

Abstract

The 6-minute walk test (6MWT) represents a comprehensive functional assessment that is commonly used in patients with heart failure; however, data are lacking in patients with transthyretin cardiac amyloidosis (ATTR-CA).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Ioannou et al. (Mon,) studied this question.

synapsesocial.com/papers/68e6a4e8b6db643587628090 https://doi.org/https://doi.org/10.1016/j.jacc.2024.04.011

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis2024 · 81 citations
2Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice?2001 · 197 citations
3Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials2023 · 54 citations
4Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction1993 · 709 citations
5Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis2022 · 53 citations

Bookmark

View Full Paper